Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2001

View Archived Issues

Novel process for synthesis of HIV protease inhibitors offered for licensing by NIH

Enzon reports Q1 2001 highlights

Neose Technologies and BMS amend cancer vaccine collaboration

VitaResc's VTR-PHP NO scavenger enters phase III testing

NIH licensing opportunity: immunogenicity-enhancing modifications of HIV env, gag and pol

Rapid and sustained symptom relief experienced by majority of IBS patients on tegaserod

Licensing opportunity from NIH: synthetic peptide vaccines elicit protective mucosal CTL response

Small molecule from Point Therapeutics stimulates hematopoiesis, advances in clinical testing

Antimicrobial magainin peptides offered for licensing by NIH

Hybridon and Isis exchange licenses to antisense-related technologies

NO scavenger AMD-6221 enhances cardiac allograft survival, particularly in combination with CsA

DDW presentations describe pharmacological profile of Z-360, a new gastrin antagonist

AnorMED halts development of AMD-3100 for treatment of HIV infection

FDA advisory committee unanimously recommends approval of Natrecor

Combination NO scavenger + ciclosporin prolongs rat cardiac allograft survival

Company Profile: OmniScience Pharmaceuticals

Avicine may be as effective as traditional chemotherapy in pancreatic cancer

FDA approves King's NDA for Levoxyl

First human results for rhAngiostatin support its further development

Company Profile: Lorantis

Antimicrobial substance produced by fungal species identified at Fujisawa

New compounds for AIDS in development at Takeda

Inhibitors of Abeta production discovered at DuPont

Pfizer describes potent new phosphodiesterase inhibitors and potential therapeutic uses

Hisamitsu's newest substance P antagonists presented in recent patent

Inhibitors of IL-6 production particularly useful in inflammatory diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...